secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-07-12T23:59:59+00:00
Accession:  0001737287-22-000049
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Allogene appoints Stephen Mayo, Ph.D. to Board; board expands to 12
-------------------------------------------------------------------

- Board increased from 11 to 12; Mayo appointed as Class III director, term expires at 2024 annual meeting.
- Annual cash retainer of $40,000 for board service under non-employee director compensation policy.
- Initial equity grants: option and RSU each with $425,000 grant date value, vesting over 3 years and 3 annual installments.
- Director eligible for annual automatic option/RSU grants with $425,000 value on each annual meeting date.
- Equity grants accelerate fully upon change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000049/0001737287-22-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000049/allo-20220708.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer